U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25ClO7
Molecular Weight 436.883
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Ertugliflozin

SMILES

CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1

InChI

InChIKey=MCIACXAZCBVDEE-CUUWFGFTSA-N
InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H25ClO7
Molecular Weight 436.883
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 22:08:27 UTC 2023
Edited
by admin
on Fri Dec 15 22:08:27 UTC 2023
Record UNII
6C282481IP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Ertugliflozin
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
Systematic Name English
PF04971729
Code English
(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
Systematic Name English
ERTUGLIFLOZIN [MI]
Common Name English
β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
Systematic Name English
PF-04971729
Code English
ERTUGLIFLOZIN [ORANGE BOOK]
Common Name English
ertugliflozin [INN]
Common Name English
Ertugliflozin [WHO-DD]
Common Name English
ERTUGLIFLOZIN [USAN]
Common Name English
PF-04971729-00
Code English
MK-8835
Code English
Classification Tree Code System Code
WHO-ATC A10BD24
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
WHO-ATC A10BK04
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C166925
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
SMS_ID
100000169082
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
EPA CompTox
DTXSID40153120
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
DRUG CENTRAL
5270
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
CAS
1210344-57-2
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
DRUG BANK
DB11827
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
PUBCHEM
44814423
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
WIKIPEDIA
Ertugliflozin
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
FDA UNII
6C282481IP
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
MERCK INDEX
m12059
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
USAN
XX-137
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
DAILYMED
6C282481IP
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
ChEMBL
CHEMBL1770248
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
EVMPD
SUB182716
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
LACTMED
Ertugliflozin
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
INN
9460
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
RXCUI
1992672
Created by admin on Fri Dec 15 22:08:27 UTC 2023 , Edited by admin on Fri Dec 15 22:08:27 UTC 2023
PRIMARY
Related Record Type Details
Structure of Ertugliflozin
EXCRETED UNCHANGED
URINE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Structure of Ertugliflozin
CUMULATIVE EXCRETION
FECAL
SODIUM/GLUCOSE COTRANSPORTER 2
TRANSPORTER -> INHIBITOR
IC50
Structure of Ertugliflozin pidolate
SALT/SOLVATE -> PARENT
SODIUM/GLUCOSE COTRANSPORTER 2
TARGET -> INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A4
METABOLIC ENZYME -> INHIBITOR
IC50
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
Structure of Ertugliflozin
CUMULATIVE EXCRETION
URINE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> INHIBITOR
IC50
Structure of Ertugliflozin
EXCRETED UNCHANGED
FECAL
Related Record Type Details
Structure of PF-06685948
METABOLITE -> PARENT
(PLASMA CIRCULATION) 12.2%, (URINE) 5.7%, (FECES) N.D.%, AFTER ADMINISTRATION OF A SINGLE 25-MG (100 MICROCURIE) ORAL DOSE OF (14C)-ERTUGLIFLOZIN (N=6, ALL MALE)
IN-VIVO
PLASMA; URINE
ERTUGLIFLOZIN METABOLITE M1
METABOLITE -> PARENT
(PLASMA CIRCULATION) 2.5%, (URINE) 0.7%, (FECES) 1.7%, AFTER ADMINISTRATION OF A SINGLE 25-MG (100 MICROCURIE) ORAL DOSE OF (14C)-ERTUGLIFLOZIN (N=6, ALL MALE)
IN-VIVO
FECAL; PLASMA; URINE
Structure of ERTUGLIFLOZIN-3-O-GLUCURONIDE
METABOLITE -> PARENT
(PLASMA CIRCULATION) 24.1%, (URINE) 31.7%, (FECES) N.D.%, AFTER ADMINISTRATION OF A SINGLE 25-MG (100 MICROCURIE) ORAL DOSE OF (14C)-ERTUGLIFLOZIN (N=6, ALL MALE)
IN-VIVO
PLASMA; URINE
Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(R)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
METABOLITE -> PARENT
Structure of 1,6-Anhydro-1-C-[4-chloro-3-[(S)-(4-ethoxyphenyl)hydroxymethyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
METABOLITE -> PARENT
Related Record Type Details
Structure of Ertugliflozin
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC DOSE
PHARMACOKINETIC
ROUTE OF ADMINISTRATION
PHARMACOKINETIC
DOSE
PHARMACOKINETIC
Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC
DOSE
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966